Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia

Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia

Of patients with advanced non-small-cell lung cancer (NSCLC), 5–10% have interstitial pneumonia (IP) at the time of diagnosis. To avoid fatal acute exacerbations of pre-existing IP, appropriate patient selection and low-risk treatment choices are warranted. Risk factors for acute exacerbation of pre...

Full description

Bibliographic Details
Main Authors: Satoshi Ikeda, Terufumi Kato, Hirotsugu Kenmotsu, Akimasa Sekine, Tomohisa Baba, Takashi Ogura
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
non-small-cell lung cancer
interstitial pneumonia
idiopathic pulmonary fibrosis
acute exacerbation
pneumonitis
cytotoxic drug
Online Access:https://www.mdpi.com/2072-6694/13/16/3979

Internet

https://www.mdpi.com/2072-6694/13/16/3979

Similar Items